期刊
JOURNAL OF INFECTIOUS DISEASES
卷 204, 期 3, 页码 415-418出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir282
关键词
-
资金
- Bristol-Myers Squibb
- Gilead Sciences
- Novartis
- Roche
- Merck
- Foundation for Liver Research (SLO), Rotterdam, the Netherlands
Nucleos(t)ide analogues strongly inhibit viral replication in chronic hepatitis B (CHB) infection, but knowledge of their long-term effect on serum hepatitis B surface antigen (HBsAg) levels and HBsAg loss is lacking. Seventy-five CHB patients with virological response (VR) to ETV or TDF were included. HBsAg decline 2 years after VR was most pronounced in HBeAg-positive patients. Age, alanine aminotransferase, and HBeAg loss were associated with HBsAg decline in HBeAg-positive patients. Predicted median time to HBsAg loss was 36 years for HBeAg-positive and 39 years for HBeAg-negative patients. Thus, most patients treated with ETV and TDF will probably need decades of therapy to achieve HBsAg loss.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据